

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of:

Examiner:

Unassigned

Yiwen Tang et al.

Serial No. 10/812,780 Art Unit:

1615

Filed:

March 29, 2004

Title:

Biologically Degradable Compositions for Medical Applications

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§1.97-1.98

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. See, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicants have not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and other non-patent documents have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

١

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: July 15, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P. One Maritime Plaza, Suite 300 San Francisco, CA 94111

Telephone (415) 954-0200 Facsimile (415) 393-9887 Respectfully submitted,

Mark Lupkowski, Ph.D. Attorney for Applicants

Reg. No. 49,010

PTO/SB/21 (08-00)

10/812.780

March 20, 2004

July 15, 2004

Date

ase type a plus sign (+) inside this box --> Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
dider the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 

Eiling Date

TRANSMITTAL

,			I ming bate	Watch 25, 2004		
FORM			First Named Inventor	Yiwen Tang		
(to be used for all correspondence after initial filtre			Group Art Unit	1615		
			Examiner Name	Unknown		
Total Number of Pag (excluding reference	ges in This Submissio s)	<sup>n</sup> 13	Attorney Docket Number	50623.280		
		ENCL	OSURES (check all that apply)			
Deposit Account C	07-1850	Assign	ment Papers Application)	After Allowance Communication to Group		
Postage Paid Ret	urn Postcard		g(s) In/Formal Sheets with ssion of Drawings Transmittal	Appeal Communication to Board of Appeals and Interferences		
Amendment / Res	ponse	Licensi	ing-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
Amendment Trans duplicate)	smittal Letter (in	Petitio	1	Proprietary Information		
Affidavits/decl	laration(s)		n to Convert to a onal Application	Status Letter		
Petition for Extension of Time (			of Attorney, Revocation e of Correspondence Address	Other Enclosure(s) (please identify below):		
☐ Information Disclosure Statement (in duplicate) with Form PTO-1449 citing 235 References			al Disclaimer st for Refund	31 Foreign Patent Documents; 21 Other Documents		
Express Mail Labe	el No.	CD, No	mber of CD(s)			
Certified Copy of I	Priority	Rema	rks	•		
Response to Miss Incomplete Applic			•			
Response to Missing Parts under 37 CFR 1.52 or 1.53						
	SIGNA	TURE OF	APPLICANT, ATTORNEY, C	RAGENT		
Firm Squire, Sanders & Mark Lupkowski, F						
Signature	Mall	ly	lun /			
Date	July <u>/5</u> , 2004	. 70				
		CE	RTIFICATE OF MAILING			
I hereby certify that th	is correspondence is	being depo	sited with the United States Post	al Service as first class mail in an envelope		

Patents, Washington, DC 20231.

addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: July 15, 2004

Typed or printed name

Signature

Dilora-Haddad

FORM PTO-1449 (Modified)

for use through 10/31/2002

US DEPARTMENT OF

US Patent and Trademark Office

Docket No. 50623.280 Application No. 10/812,780

INFORMATION DISCLOSURE CITATION in an Application

Applicant

Yiwen Tang et al.

(Use several sheets if necessary)

Filing Date Group Art Unit
March 29, 2004 1615

U.S. PATENT DOCUMENTS  Examiner Ref. No. Document Date of Name Class Subclass Filing Date							
Initial	Rei. No.	Number	Patent	Name	Ciass	Subciass	Appropriate
/A.F./	A1	3,839,743	10/8/74	Schwarcz	3	1	
	A2	3,900,632	8/19/75	Robinson	428	196	
	А3	4,110,497	8/29/78	Hoel	428	190	
	A4	4,321,711	3/30/82	Mano	3	1.4	
	A5	4,346,028	8/24/82	Griffith	524	417	
	A6	4,633,873	1/6/87	Dumican et al.	128	334	
	A7	4,656,083	4/7/87	Hoffman et al.	428	265	
	A8	4,718,907	1/12/88	Karwoski et al.	623	12	
	A9	4,722,335	2/2/88	Vilasi	128	207.14	
	A10	4,723,549	2/9/88	Wholey et al.	128	344	
	A11 .	4,732,152	3/22/88	Wallstén et al.	128	343	
	A12	4,733,665	3/29/88	Palmaz	128	343	
	A13	4,739,762	4/26/88	Palmaz	128	343	
	A14	4,740,207	4/26/88	Kreamer	623	1	
	A15	4,743,252	5/10/88	Martin, Jr. et al.	623	1.	
	A16	4,768,507	9/6/88	Fischell et al.	128	303	
	A17	4,776,337	10/11/88	Palmaz	128	343	
	A18	4,816,339	3/28/89	Tu et al.	428	421	
	A19	4,850,999	7/25/89	Planck	623	1	
	A20	4,877,030	10/31/89	Beck et al.	128	343	
_	A21	4,878,906	11/7/89	Lindemann et al.	623	1	
	A22	4,879,135	11/7/89	Greco et al.	427	2	
	A23	4,902,289	2/20/90	Yannas	623	1	
	A24	4,977,901	12/18/90	Ofstead	128	772	
V	A25	4,994,298	2/19/91	Yasuda	427	41	
/A.F./	A26	5,019,090	5/28/91	Pinchuk	606	194	

/A.F./	A27	5,028,597	7/2/91	Kodama et al.	514	56	
	A28	5,059,211	10/22/91	Stack et al.	606	198	
	A29	5,062,829	11/5/91	Pryor et al.	604	57	
	A30	5,084,065	1/28/92	Weldon et al.	623	1	
	A31	5,085,629	2/4/92	Goldberg et al.	604	8	
$\top$	A32	5,100,429	3/31/92	Sinofsky et al.	606	195	
	A33	5,108,755	4/28/92	Daniels et al.	424	426	
	A34	5,112,457	5/12/92	Marchant	204	165	
	A35	5,123,917	6/23/92	Lee	623	1	
	A36	5,156,623	10/20/92	Hakamatsuka et al.	623	11	
	A37	5,163,951	11/17/92	Pinchuk et al.	623	1	
	A38	5,163,952	11/17/92	Froix	623	1	
	A39	5,163,958	11/17/92	Pinchuk	623	11	
	A40	5,167,614	12/1/92	Tessmann et al.	604	8	
	A41	5,192,311	3/9/93	King et al.	623	1	
	A42	5,197,977	3/30/93	Hoffman, Jr. et al.	623	1	
	A43	5,234,456	8/10/93	Silvestrini	606	194	
	A44	5,234,457	8/10/93	Andersen	606	198	
	A45	5,236,447	8/17/93	Kubo et al.	623	1	
	A46	5,279,594	1/18/94	Jackson	604	265	
	A47	5,282,860	2/1/94	Matsuno et al.	623	12	
	A48	5,289,831	3/1/94	Bosley	128	899	
	A49	5,290,271	3/1/94	Jernberg	604	891.1	
	A50	5,306,286	4/26/94	Stack et al.	606	198	
	A51	5,306,294	4/26/94	Winston et al.	623	1	
	A52	5,328,471	7/12/94	Slepian	604	101	
	A53	5,330,500	7/19/94	Song	606	198	
	A54	5,342,348	8/30/94	Kaplan	604	891.1	
	A55	5,342,395	8/30/94	Jarrett et al.	606	219	
	A56	5,342,621	8/30/94	Eury	424	423	
	A57	5,356,433	10/18/94	Rowland et al.	623	11	
V	A58	5,383,925	1/24/95	Schmitt	623	1	
/A.F./	A59	5,385,580	1/31/95	Schmitt	623	1	

/A.F./	A60	5,389,106	2/14/95	Tower	606	198	
	A61	5,441,515	8/15/95	Khosravi et al.	606	194	
	A62	5,443,458	8/22/95	Eury	604	891.1	
	A63	5,455,040	10/3/95	Marchant	424	426	
	A64	5,464,650	11/7/95	Berg et al.	427	2.30	
	A65	5,502,158	3/26/96	Sinclair et al.	528	354	
	A66	5,514,379	5/7/96	Weissleder et al.	424	426	
	A67	5,527,337	6/18/96	Stack et al.	606	198	
	A68	5,554,120	9/10/96	Chen et al.	604	96	
	A69	5,556,413	9/17/96	Lam	606	198	
$\neg \vdash$	A70	5,578,046	11/26/96	Liu et al.	606	151	
	A71	5,578,073	11/26/96	Haimovich et al.	623	1	
$\top$	A72	5,591,607	1/7/97	Gryaznov et al.	435	91.1	
$\top$	A73	5,593,403	1/14/97	Buscemi	606	2	_
	A74	5,593,434	1/14/97	Williams	623	1	
$\top$	A75	5,599,301	2/4/97	Jacobs et al.	604	65	
$\top$	A76	5,599,922	2/4/97	Gryaznov et al.	536	25.3	
$\top$	A77	5,605,696	2/25/97	Eury et al.	424	423	
$\top$	A78	5,629,077	5/13/97	Turnlund et al.	442	38	
$\top$	A79	5,631,135	5/20/97	Gryaznov et al.	435	6	
$\top$	A80	5,637,113	6/10/97	Tartaglia et al.	623	1	
	A81	5,667,767	9/16/97	Greff et al.	424	9.411	
十	A82	5,670,558	9/23/97	Onishi et al.	523	112	
	A83	5,693,085	12/2/97	Buirge et al.	623	1	
	A84	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A85	5,707,385	1/13/98	Williams	606	192	
	A86	5,716,981	2/10/98	Hunter et al.	514	449	
	A87	5,726,297	3/10/98	Gryaznov et al.	536	22.1	
$\top$	A88	5,725,549	3/10/98	Lam	606	198	
	A89	5,728,751	3/17/98	Patnaik	523	112	
	A90	5,733,925	3/31/98	Kunz et al.	514	449	
V	A91	5,741,881	4/21/98	Patnaik	528	75	
/A.F./	A92	5,756,457	5/26/98	Wang et al.	514	12	

/A.F./	A93	5,756,476	5/26/98	Epstein et al.	514	44	
T	A94	5,766,710	6/16/98	Turnlund et al.	428	36.1	
	A95	5,800,516	9/1/98	Fine et al.	623	1	
-	A96	5,811,447	9/22/98	Kunz et al.	514	411	
	A97	5,824,049	10/20/98	Ragheb et al.	623	1	
	A98	B1 4,739,762	10/27/98	Palmaz (Reexamination Certificate)	606	108	
	A99	5,830,178	11/3/98	Jones et al.	604	49	
	A100	5,830,461	11/3/98	Billiar	424	94.4	
$\top$	A101	5,830,879	11/3/98	Isner	514	44	
	A102	5,833,651	11/10/98	Donovan et al.	604	53	
	A103	5,834,582	11/10/98	Sinclair et al.	528	354	
	A104	5,837,313	11/17/98	Ding et al.	427	2.21	
	A105	5,837,835	11/17/98	Gryaznov et al.	536	23.1	
T .	A106	5,851,508	12/22/98	Greff et al.	424	-9.411	
	A107	5,854,207	12/29/98	Lee et al.	514	2	
	A108	5,855,618	1/5/99	Patnaik et al.	623	11	
	A109	5,858,746	1/12/99	Hubbell et al.	435	177	
$\top$	A110	5,865,814	2/2/99	Tuch	604	265	
	A111	5,873,904	2/23/99	Ragheb et al.	623	1	
$\top$	A112	5,874,165	2/23/99	Drumheller	428	308.4	
	A113	5,876,743	3/2/99	Ibsen et al.	424	426	
	A114	5,877,263	3/2/99	Patnaik et al.	525	453	
	A115	5,879,713	3/9/99	Roth et al.	424	489	
	A116	5,891,192	4/6/99	Murayama et al.	623	1	
1	A117	5,897,955	4/27/99	Drumheller	428	422	
	A118	5,914,182	6/22/99	Drumheller	428	308.4	
	A119	5,916,870	6/29/99	Lee et al.	514	2	
	A120	5,942,209	8/24/99	Leavitt et al.	424	1.25	
	A121	5,948,428	9/7/99	Lee et al.	424	426	
1	A122	5,957,975	9/28/99	Lafont et al.	623	1	
$\top$	A123	5,965,720	10/12/99	Gryaznov et al.	536	23.1	
$\overline{\mathbb{V}}$	A124	5,971,954	10/26/99	Conway et al.	604	96	
/A.F./	A125	5,980,564	11/9/99	Stinson	623	1	

/A.F./	A126	5,980,928	11/9/99	Terry	424	427	
	A127	5,980,972	11/9/99	Ding	427	2.24	
	A128	5,981,568	11/9/99	Kunz et al.	514	411	
	A129	5,997,468	12/7/99	Wolff et al.	600	36	
	A130	6,015,541	1/18/00	Greff et al.	424	1.25	
	A131	6,042,875	3/28/00	Ding et al.	427	2.24	
	A132	6,048,964	4/11/00	Lee et al.	530	350	
	A133	6,051,648	4/18/00	Rhee et al.	525	54.1	
	A134	6,056,993	5/2/00	Leidner et al.	427	2.25	
	A135	6,060,451	5/9/00	DiMaio et al.	514	13	
	A136	6,071,266	6/6/00	Kelley	604	265	
	A137	6,074,659	6/13/00	Kunz et al.	424	423	
	A138	6,080,177	6/27/00	Igaki et al.	606	198	
	A139	6,080,488	6/27/00	Hostettler et al.	428	423.3	
	A140	6,093,463	7/25/00	Thakrar	428	36.9	
	A141	6,096,070	8/1/00	Ragheb et al.	623	1	
	A142	6,096,525	8/1/00	Patnaik	435	181	
	A143	6,099,562	8/8/00	Ding et al.	623	1.46	
	A144	6,103,230	8/15/00	Billiar et al.	424	94.4	
	A145	6,107,416	8/22/00	Patnaik et al.	525	453	
$\top$	A146	6,110,188	8/29/00	Narciso, Jr.	606	153	
	A147	6,113,629	9/5/00	Ken	623	1.1	
	A148	6,117,979	9/12/00	Hendriks et al.	530	356	
	A149	6,120,536	9/19/00	Ding et al.	623	1.43	
	A150	6,120,904	9/19/00	Hostettler et al.	428	423.3	
	A151	6,121,027	9/19/00	Clapper et al.	435	180	
	A152	6,127,173	10/3/00	Eckstein et al.	435	320.1	
	A153	6,129,761	10/10/00	Hubbell	623	11	
	A154	6,153,252	11/28/00	Hossainy et al.	427	2.3	
	A155	B1 4,776,337	12/5/00	Palmaz (Reexamination Certificate)	606	108	
	A156	6,159,951	12/12/00	Karpeisky et al.	514	45	
V	A157	6,165,212	12/26/00	Dereume et al.	623	1.13	
/A.F./	A158	6,166,130	12/26/00	Rhee et al.	525	54.1	

A.F./	A159	6,169,170	1/2/01	Gryaznov et al.	536	23.1		
T	A160	6,171,609	1/9/01	Kunz	424	422	-	-
+-	A161	6,174,330	1/16/01	Stinson	623	1.34		
+	A162	6,177,523	1/23/01	Reich et al.	525	459		
+	A163	6,224,626	5/1/01	Steinke	623	1.16	_	
+	A164	6,228,845	5/8/01	Donovan et al.	514	44		
+	A165	6,240,616	6/5/01	Yan	29	527.2		
+	A166		6/12/01	Stinson	623	1.22		
	<del> </del>	6,245,103			623	1.34		
+-	A167	6,251,135	6/26/01	Stinson et al.	+	_		
	A168	6,251,142	6/26/01	Bernacca et al.	623	23.57		
-	A169	6,287,332	9/11/01	Bolz et al.	623	1.15		
-	A170	6,423,092	7/23/02	Datta et al.	623	1.15		
-	A171	6,527,801	3/4/03	Dutta	623	1.46		
	A172	6,626,939	9/30/03	Burnside et al.	623	1.38		
	A173	6,656,162	12/2/03	Santini, Jr. et al.	604	191		
_	A174	6,746,773	6/8/04	Llanos et al.	428	421		
	A175	6,752,826	6/22/04	Holloway et al.	623	1.13		
	A176	4,733,665 C2	1/29/02	Palmaz (Reexamination Certificate)	606	108		
	A177	2002/0002399	1/3/02	Huxel et al.	623	1.15		
	A178	2002/0004060	1/10/02	Heublein et al.	424	422		
	A179	2002/0004101	1/10/02	Ding et al.	427	261		
	A180	2002/0116050	8/22/02	Kocur	623	1.15		
	A181	2003/0105518	6/5/03	Dutta	623	1.38		
$\Psi_{-}$	A182	2003/0100865	5/29/03	Santini, Jr. et al.	604	161		
/A.F./	A183	2004/0098095	5/20/04	Burnside et al.	623	1.13		
				N PATENT DOCUMENTS				
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Trans Yes	lation No
/A.F./	B1	EP 0 108 171	5/16/84	European				
I	B2	EP 0 144 534	6/19/85	European				
	В3	WO 89/03232	4/20/89	PCT				
	B4	WO 90/01969	3/8/90	PCT				
$\nabla$	B5	EP 0 364 787	4/25/90	European				
/A.F./	В6	WO 90/04982	5/17/90	PCT		<del> </del>		

В7	WO 90/06094	6/14/90	PCT				
В8	EP 0 397 500	11/14/90	European				
В9	WO 91/17744	11/28/91	PCT				
B10	WO 91/17789	11/28/91	PCT				
B11	EP 0 464 755	1/8/92	European				
B12	GB 2 247 696	3/11/92	Great Britain				
B13	WO 92/10218	6/25/92	PCT				
B14	EP 0 493 788	7/8/92	European				
B15	WO 93/06792	4/15/93	PCT				
B16	EP 0 554 082	8/4/93	European				
B17	EP 0 578 998	1/19/94	Ешореан			×	
B18	EP 0 604 022	6/29/94	European				
B19	DE 44 07 079	9/29/94	German	, " '5 '5" .		х	
B20	WO 94/21196	9/29/94	PCT				
B21	EP 0 621 017	10/26/94	European				
B22	EP 0 623 354	11/9/94	European				
B23	EP 0 665 023	8/2/95	European				
B24	WO 95/29647	11/9/95	PCT				
B25	DE 197 31 021	1/21/99	German			х	
B26	DE 198 56 983	12/30/99	German			х	
B27	EP 0 970 711	1/12/00	European			х	
B28	WO 00/12147	3/9/00	PCT				
B29	WO 00/64506	11/2/00	PCT				
B30	WO 01/01890	1/11/01	PCT				
B31	WO 2004/023985	3/25/04	PCT				
	OTHER DO	CUMENT	S (Including Author, Title, Date, Pertine	nt Pages, etc	.)		
C1	Ansari, <i>Tubal Reanasi</i> (1978).	tomosis Usi	ing Absorbable Stent, International J	ournal of Fe	rtility, Vol.	23, No.	1
C2	Ansari, End-to-end tub 201 (August 1979).	al anastom	osis using an absorbable stent, Fer	tility and Ste	rility, Vol.	32(2), p	p. 197-
СЗ	Bull, Parylene Coating	for Medica	I Applications, Medical Product Man	ufacturing N	ews (Mar	ch 1993	).
I	Casper et al Eiher-Pe	einforced Al	bsorbable Composite for Orthopedia	Surgery. Po	olymeric N	laterials	
C4	Science and Engineer						
	B8 B9 B10 B11 B12 B13 B14 B15 B16 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 C1 C2 C3	B8	B8         EP 0 397 500         11/14/90           B9         WO 91/17744         11/28/91           B10         WO 91/17789         11/28/91           B11         EP 0 464 755         18/92           B12         GB 2 247 696         3/11/92           B13         WO 92/10218         6/25/92           B14         EP 0 493 788         7/8/92           B15         WO 93/06792         4/15/93           B16         EP 0 554 082         8/4/93           B17         EP 0 578 998         1/19/94           B19         DE 44 07 079         9/29/94           B20         WO 94/21196         9/29/94           B21         EP 0 621 017         10/26/94           B22         EP 0 623 354         11/9/94           B23         EP 0 665 023         8/2/95           B24         WO 95/29647         11/9/95           B25         DE 197 31 021         1/21/99           B26         DE 198 56 983         12/30/99           B27         EP 0 970 711         1/12/00           B28         WO 00/64506         11/2/00           B30         WO 01/01890         1/11/01           B31         WO 2004/023985<	B8	B8	B8	B8

/A.F./	C6	Detweiler et al., Sutureless Cholecystojejunostomy in Pigs Using an Absorbable Intraluminal Stent and Fibrin Glue, Journal of Investigative Surgery, Vol. 9(1), pp. 13-26 (Jan./Feb. 1996).
	C7	Detweiler et al., Sliding, Absorbable, Reinforced Ring and an Axially Driven Stent Placement Device for Sutureless Fibrin Glue Gastrointestinal Anastomisis, Journal of Investigative Surgery, Vol. 9(6), pp. 495- 504 (Nov./Dec. 1996).
	C8	Detweiler et al., Gastrointestinal Sutureless Anastomosis Using Fibrin Glue: Reinforcement of the Sliding Absorbable Intralminal Nontoxic Stent and Development of a Stent Placement Device, Journal of Investigative Surgery, Vol. 9(2), pp. 111-130 (Mar/Apr. 1996).
	C9	Devanathan et al., Polymeric Conformal Coatings for Implantable Electronic Devices, IEEE Transactions on Biomedical Engineering, Vol. BME-27(11):671-675 (1980).
	C10	Feng-Chun et al., Assessment of Tissue Blood Flow Following Small Artery Welding with an Intraluminal Dissolvable Stent, Microsurgery, Vol. 19(3), pp. 148-152 (1999).
	C11	Hahn et al., Biocompatibility of Glow-Discharge-Polymerized Films and Vacuum-Deposited Parylene, J Applied Polymer Sci, 38:55-64 (1984).
	C12	Hahn et al., Glow Discharge Polymers as Coatings for Implanted Devices, ISA, pp. 109-111 (1981).
	C13	Kelley et al., Totally Resorbable High-Strength Composite Material, Advances in Biomedical Polymers, 35:75-85 (1987).
	C14	Kubies et al., Microdomain Structure In Polylactide-block-poly(ethylene oxide) Copolymer Films, Biomaterials 21:529-536 (2000).
	C15	Kutryk et al., Coronary Stenting: Current Perspectives, companion to the Handbook of Coronary Stents (1999).
	C16	Muller et al., Advances in Coronary Angioplasty: Endovascular Stents, Coron Arter Dis, 1(4):438-448 (Jul/Aug. 1990).
	C17	Nichols et al., Electrical Insulation of Implantable Devices by Composite Polymer Coatings, ISA Transactions, 26(4):15-18 (1987).
	C18	Redman, Clinical Experience with Vasovasostomy Utilizing Absorbable Intravasal Stent, Urology, Vol. 20(1), pp. 59-61 (July 1982).
	C19	Rust et al., The Effects of Absorbable Stenting on Postoperative Stenosis of the Surgically Enlarged Maxillary Sinus Ostia in a Rabbit Animal Model, Archives of Otolaryngology, Vol. 122(12), pp. 1395-1397 (December 1996).
V	C20	Schatz, A View of Vascular Stents, Circulation, 79(2):445-457 (Feb. 1989).
/A.F./	C21	Schmidt et al., Long-Term Implants of Parylene-C Coated Microelectrodes, Med & Biol Eng & Comp, 26(1):96-101 (Jan. 1988).
XAMINER	-	/Abigail Fisher/ DATE CONSIDERED 10/09/2007

EXAMINER: Initial if references considered, whether or not cliation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.